The influencing factors of the erythropoietin resistance index and its association with all-cause mortality in maintenance hemodialysis patients

References

• Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):1–8. doi: 10.1159/000514550.
   PubMed Web of Science ®Google Scholar
• Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294–1304. doi: 10.1001/jama.2019.14745.
   PubMed Web of Science ®Google Scholar
• GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–733. doi: 10.1016/S0140-6736(20)30045-3.
   PubMed Web of Science ®Google Scholar
• Yang C, Gao B, Zhao X, et al. Executive summary for China kidney disease network (CK-NET) 2016 annual data report. Kidney Int. 2020;98(6):1419–1423. doi: 10.1016/j.kint.2020.09.003.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–1634. doi: 10.1681/ASN.2011111078.
   PubMed Web of Science ®Google Scholar
• Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015;162(11):ITC1–IT16. doi: 10.7326/AITC201506020.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in hemodialysis patients of five european countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (DOPPS) [published correction appears in nephrol dial transplant. 2004 jun;19(6):1666]. Nephrol Dial Transplant. 2004;19(1):121–132. doi: 10.1093/ndt/gfg458.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Coyne DW. How I treat renal anemia. Blood. 2020;136(7):783–789. doi: 10.1182/blood.2019004330.
   PubMed Web of Science ®Google Scholar
• Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):677–690. doi: 10.1053/j.ajkd.2016.04.018.
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A, Kidney Disease: improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–830. doi: 10.7326/0003-4819-158-11-201306040-00007.
   PubMed Web of Science ®Google Scholar
• Fort J, Cuevas X, García F, et al. Mortality in incident hemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrol Dial Transplant. 2010;25(8):2702–2710. doi: 10.1093/ndt/gfq073.
   PubMed Web of Science ®Google Scholar
• Joksimovic Jovic J, Antic S, Nikolic T, et al. Erythropoietin resistance development in hemodialysis patients: the role of oxidative stress. Oxid Med Cell Longev. 2022;2022:9598210–9598211. doi: 10.1155/2022/9598211.
   Web of Science ®Google Scholar
• Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in hemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26(8):2641–2648. doi: 10.1093/ndt/gfq802.
   PubMed Web of Science ®Google Scholar
• Pınarbaşı AS, Dursun I, Günay N, et al. Erythropoietin resistance index and the affecting factors in children with peritoneal dialysis. Blood Purif. 2021;50(6):942–951. doi: 10.1159/000514060.
   PubMed Web of Science ®Google Scholar
• Pan S, Zhao DL, Li P, et al. Relationships among the dosage of erythropoiesis-stimulating agents, erythropoietin resistance index, and mortality in maintenance hemodialysis patients. Blood Purif. 2022;51(2):171–181. doi: 10.1159/000506536.
   PubMed Web of Science ®Google Scholar
• Sun YP, Yang WJ, Li SH, et al. Clinical epidemiology of mineral bone disorder markers in prevalent hemodialysis patients in the xinjiang uyghur autonomous region in China. Biomed Res Int. 2017;2017:2516934–2516935. doi: 10.1155/2017/2516934.
   PubMed Web of Science ®Google Scholar
• Zhao X, Niu Q, Gan L, et al. Blood flow rate: an independent risk factor of mortality in chinese hemodialysis patients. Semin Dial. 2022;35(3):251–257. doi: 10.1111/sdi.13023.
   PubMed Web of Science ®Google Scholar
• Niu Q, Zhao X, Gan L, et al. Physical function and clinical outcomes in hemodialysis patients: China dialysis outcomes and practice patterns study. Kidney Dis. 2021;7(4):315–322. doi: 10.1159/000513897.
   Google Scholar
• Zhao X, Niu Q, Gan L, et al. Thrombocytopenia predicts mortality in chinese hemodialysis patients- an analysis of the China DOPPS. BMC Nephrol. 2022;23(1):11. Published 2022 Jan 3. doi: 10.1186/s12882-021-02579-5.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet. 2021;398(10302):786–802. doi: 10.1016/S0140-6736(21)00519-5.
   PubMed Web of Science ®Google Scholar
• Ma L, Zhao S. Risk factors for mortality in patients undergoing hemodialysis: a systematic review and meta-analysis. Int J Cardiol. 2017;238:151–158. doi: 10.1016/j.ijcard.2017.02.095.
   PubMed Web of Science ®Google Scholar
• Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308(22):2349–2360. doi: 10.1001/jama.2012.16817.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl, 2 (2012), pp. 279–335
   Google Scholar
• Guideline Working Group for renal anemia, Chinese Medical Doctor Association Branch of Nephrophysicians. Clinical guidelines for diagnosis and treatment of renal anemia in China. Chin J Med. 2021;101(20):40.
   Google Scholar
• Fukuma S, Yamaguchi T, Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012;59(1):108–116. doi: 10.1053/j.ajkd.2011.07.014.
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y, Hamano T, Wada A, et al. Types of erythropoietin-Stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30(6):1037–1048. doi: 10.1681/ASN.2018101007.
   PubMed Web of Science ®Google Scholar
• Feret W, Safranow K, Kwiatkowska EWA, et al. Malnutrition and erythropoietin resistance among patients with end-stage kidney disease: where is the perpetrator of disaster? Nutrients. 2022;14(24):5318.doi: 10.3390/nu14245318.
   PubMed Web of Science ®Google Scholar
• Chiang WF, Hsiao PJ, Wu KL, et al. Investigation of the relationship between lean muscle mass and erythropoietin resistance in maintenance hemodialysis patients: a cross-sectional study. Int J Environ Res Public Health. 2022;19(9):5704. doi: 10.3390/ijerph19095704.
   PubMed Web of Science ®Google Scholar
• López-Gómez JM, Portolés JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008;74(111):S75–S81. doi: 10.1038/ki.2008.523.
   Google Scholar
• Okazaki M, Komatsu M, Kawaguchi H, et al. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif. 2014;37(2):106–112. doi: 10.1159/000358215.
   PubMed Web of Science ®Google Scholar
• Goodkin DA, Zhao J, Cases A, et al. Resistance to erythropoiesis-stimulating agents among patients on hemodialysis is typically transient. Am J Nephrol. 2022;53(5):333–342. doi: 10.1159/000523947.
   PubMed Web of Science ®Google Scholar
• Arrieta J, Moina I, Molina J, et al. Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability. Int J Nephrol Renovasc Dis. 2014;7:353–359. doi: 10.2147/IJNRD.S6189525336984.
   PubMedGoogle Scholar
• Kobayashi S, Tanaka K, Hoshino J, et al. Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis. Ren Fail. 2022;44(1):1801–1810. doi: 10.1080/0886022X.2022.2106873.
   PubMed Web of Science ®Google Scholar
• Chait Y, Kalim S, Horowitz J, et al. The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure. Hemodial Int. 2016;20(3):392–398. doi: 10.1111/hdi.12407.
   PubMed Web of Science ®Google Scholar